We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 97.50 | 95.00 | 100.00 | 97.50 | 97.50 | 97.50 | 5,188 | 07:36:53 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -4.46 | 13M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/2/2022 13:56 | This Institution of Engineering and Technology (IET) report sets out our position on the digital transformation of the National Health Service (NHS) and social care across England. While the NHS has faced and met the greatest challenge of its 73-year history in the Covid-19 pandemic, preparatory work has continued towards the long-term goal of ensuring widespread interoperability across the sector..https://www. | ragnarr | |
25/2/2022 09:55 | Just dropped by to see how Captain Tom's pension scheme was going. It seems it's doing quite well for him despite the usual lack of anyone actually wanting to buy his transformational product offering. Unbelievable.. | davwal | |
23/2/2022 20:39 | Yump, I would love to have something to ramp! Every RNS makes me cringe. The claim that TO held a certain percentage of the stock! Absolutely misleading, the %age was his options, he has not, to this date invested a penny in the company, despite earning more than the prime minister. His cringeworthy video interview proclaiming a 9% increase in revenue! Oh Lord. £10b addressable revenue! Embarrassing. I do continue to hold as I do believe the potential is very good but oh my word it is hard work. These Clowns will really have to deliver solid revenue before the market reacts. Here’s hoping! | ducatiman | |
23/2/2022 17:02 | Courtesy of Vascular over on LSE - position now closedhttps://uk.tra | ragnarr | |
23/2/2022 15:25 | Uncritical regulars and rampers ? Posting on the wrong thread I think. Challenge: Find a ramper here. Good luck with that. | yump | |
23/2/2022 15:12 | Why not Duc, I've seen plenty of other companies do similar? More convinced than ever that we will have plenty of good news in the next two months. | lr2 | |
23/2/2022 14:19 | LR2 - more than likely but yet another kick in the gonads for us plebs under the guise of our supposedly benefitting from any good news as well as them. | digger2779 | |
23/2/2022 13:54 | Are they allowed to do that LR2? | ducatiman | |
23/2/2022 13:40 | News soon then now the options have been granted. | lr2 | |
23/2/2022 11:21 | At least something is ahead of expectations. | orange1 | |
23/2/2022 09:49 | These option awards are certainly ahead of expectations | photon | |
23/2/2022 08:20 | held this puppy too long | middlesboroughfc | |
23/2/2022 08:19 | Tom getting more options for delivering zero. | 1bond | |
23/2/2022 08:05 | Performance related options mind. But sadly the vesting conditions are related to the company's share price rather than how the company's business is doing. | orange1 | |
23/2/2022 07:27 | Quite often directors will buy shares to support the share price if they feel the market is undervaluing their company. Here it would seem they take advantage of a weak share price by granting options. | ducatiman | |
19/2/2022 19:35 | Just wish ydderF would go post on the IQAI board instead of here. Talk about holding a grudge. | lr2 | |
19/2/2022 19:23 | Just wish fybberF could afford to buy Texrad. | ducatiman | |
19/2/2022 19:07 | TexRAD still in use. Diagnostic performance of CT lung severity score and quantitative chest CT for stratification of COVID-19 patients 'Texture analysis was performed by using a dedicated software (TexRAD, Feedback Medical Ltd., Cambridge, UK). Statistical analysis was performed using MedCalc Statistical Software version 17.9.7 (MedCalc Software bvba, Ostend, Belgium).' | lr2 | |
19/2/2022 18:47 | Raising £11.2m no mean feat. Walter Mithof or entrepreneurial genius? We still don’t know but it won’t be too long now. If the latter I doubt we will hear from fybberF again. | ducatiman | |
19/2/2022 08:56 | LR2 and other uncritical regulars here, Buywell is pointing out the lack of progress in ten years. Though the facts speak for themselves, anyone newly coming to this cosy club of uncritical supporters should be able to make their minds up from a balanced mix of views. Fact is the reams of positive posts with any basis over the years (see the chart) have self-evidently been fantasy. The most successful operation the Company has executed has been to raise millions with the continuous issue of huge numbers of shares. Here is a simple question to you LR2, as a shareholder. How has it benefited your net worth in this investment over the years that this has happened? ...and a second simple question, who has benefitted? One thing all objective holders can agree upon is that it has been an utterly appalling investment for anyone buying in any one of the last 10 years, quite shocking | ydderf | |
18/2/2022 21:27 | So Buywell, with no interest in this company, why are you hanging around this board? | lr2 | |
18/2/2022 20:42 | Too much ramping on next to nothing sales imo Reminds buywell of another share that was tipped for NHS bigtime take-up Attracted a star fund manager at the time that bought a big holding --- and a potential USA partner But the NHS never moved and the share price slid till it delisted free stock charts from uk.advfn.com | buywell3 | |
18/2/2022 18:07 | Courtesy of Vascular on the other place. I'd have hoped Bleepa would have had a Database Developer when it was first being developed. Maybe it's for a replacement developer. Used to love designing databases in the dim and distant past. Very satisfying. | lr2 | |
18/2/2022 13:37 | Condolences, and commiserations... | ydderf |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions